Determination of Tissue Penetration and Pharmacokinetics of Linezolid in Patients with Diabetic Foot Infections Using In Vivo Microdialysis
- 1 September 2011
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (9), 4170-4175
- https://doi.org/10.1128/aac.00445-11
Abstract
Staphylococcus aureus and other Gram-positive organisms, including methicillin-resistant S. aureus , continue to be the predominant pathogens associated with diabetic foot infections. Consequently, linezolid is often used to treat these infections. The purpose of the current study was to describe the pharmacokinetic profile and determine the level of penetration of linezolid into healthy thigh tissue and infected wound tissue of the same extremity in 9 diabetic patients with chronic lower limb infections by use of in vivo microdialysis. Hourly plasma and dialysate samples were obtained over a 12-h dosing interval following 3 to 4 doses of linezolid (600 mg intravenously every 12 h). Plasma protein binding was also assessed at 1, 6, and 12 h postdose. The means ± standard deviations (SD) for the maximum concentration in serum ( C max ), the volume of distribution at terminal phase ( V z ), and the half-life ( t 1/2 ) for linezolid in plasma were 11.99 ± 3.67 μg/ml, 0.71 ± 0.25 liters/kg of body weight, and 4.71 ± 1.23 h, respectively. Mean protein binding was 14.78% (range, 3.85 to 32.03%). The mean areas under the concentration-time curves from 0 to 12 h for the free, unbound fraction of linezolid ( f AUC 0–12 values) ± SD for plasma, wound tissue, and thigh tissue were 51.24 ± 12.72, 82.76 ± 59.01, and 92.52 ± 60.44 μg · h/ml, respectively. Tissue penetration ratios (tissue f AUC to plasma f AUC) were similar for thigh (1.42; range, 1.08 to 2.23) and wound (1.27; range, 0.86 to 2.26) tissues ( P = 0.648). With the currently approved dosing regimen, linezolid penetrated well into both healthy thigh tissue and infected wound tissue in these diabetic patients.This publication has 28 references indexed in Scilit:
- Tissue Penetration and Pharmacokinetics of Tigecycline in Diabetic Patients with Chronic Wound Infections Described by Using In Vivo MicrodialysisAntimicrobial Agents and Chemotherapy, 2010
- Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infectionsInternational Journal of Antimicrobial Agents, 2010
- Cellular Pharmacokinetics of the Novel Biaryloxazolidinone Radezolid in Phagocytic Cells: Studies with Macrophages and Polymorphonuclear NeutrophilsAntimicrobial Agents and Chemotherapy, 2010
- Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell linesJournal of Antimicrobial Chemotherapy, 2009
- In Vivo Microdialysis Study of the Penetration of Daptomycin into Soft Tissues in Diabetic versus Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2008
- Clinical Microdialysis in Skin and Soft Tissues: An UpdateThe Journal of Clinical Pharmacology, 2008
- Pharmacokinetics of Unbound Linezolid in Plasma and Tissue Interstitium of Critically Ill Patients after Multiple Dosing Using MicrodialysisAntimicrobial Agents and Chemotherapy, 2006
- Diagnosing and treating diabetic foot infectionsDiabetes/Metabolism Research and Reviews, 2004
- Clinical Pharmacodynamics of Linezolid in Seriously Ill Patients Treated in a Compassionate Use ProgrammeClinical Pharmacokinetics, 2003
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976